Universitätsmedizin Göttingen, Georg-August-Universität

Göttingen 37099

1 studies enrolling now · 21 studies all time

What they study most

Atopic Dermatitis, Atrial Fibrillation, Breast Cancer, Extensive-stage Small Cell Lung Cancer (ES-SCLC), Geographic Atrophy, Heart Failure, Hidradenitis Suppurativa, Leukemia, Myeloid, Acute, Lupus Nephritis, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Myocardial Infarction

Studies at this site

• DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy — Recruiting now
• A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis — Recruiting now
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy — Running, not enrolling
• Vamikibart in Participants With Uveitic Macular Edema — Completed
• This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) — Completed
• Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa — Completed
• Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis — Completed
• Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction — Completed
• A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD) — Completed
• Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) — Completed
• A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration — Completed
• MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing — Stopped early
• Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) — Completed
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) — Completed
• A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis — Stopped early
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) — Completed
• Safety of Dabigatran Etexilate in Blood Clot Prevention in Children — Completed
• Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI) — Completed
• REVEAL AF: Incidence of AF in High Risk Patients — Completed
• Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT) — Completed
• Safety and Clinical Performance of the Protecta ICD and CRT-D — Completed